Home » AstraZeneca’s Tagrisso Approved in China for NSCLC
AstraZeneca’s Tagrisso Approved in China for NSCLC
March 30, 2017
The China Food and Drug Administration approved Tagrisso for the treatment of EGFR T790M mutation-positive, locally-advanced or metastatic non-small cell lung cancer in adults whose disease progressed following first-line EGFR tyrosine kinase inhibitor therapy.
Patients are treated with Tagrisso only if they are diagnosed with EGFR T790M mutation in the tumor. The third-generation, irreversible EGFR inhibitor, is now available in more than 45 countries.
Tagrisso is also being investigated for treatment of adjuvant and metastatic first-line settings patients, with and without brain metastases, as well as for the treatment of leptomeningeal disease and in combination therapies.
Upcoming Events
-
21Oct